Understanding the Trump administration plan to show drug prices in TV adsMore
Americans are rightly concerned about the price of prescription medicines. New ideas and approaches are needed to deal with this…More
Remember the last time you turned on your television to watch a football game or catch up on the latest…More
The IQVIA Institute released a data-rich report in April 2019 on the state of clinical R&D in the US pharmaceutical…More
Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma—and just how payers…More
As far as troubled backstories go, Sarepta Therapeutics’ Exondys 51 has a doozy with a contentious approval process and a…More
Novartis made headlines last year by saying its forthcoming spinal muscular atrophy gene therapy could be cost effective at up…More
With Congress railing against rising list prices for insulin, Eli Lilly made a commitment to introduce a cheaper generic version…More
Mallinckrodt’s Acthar Gel is no stranger to controversy. Pricing critics, payers, and the feds have all targeted the controversial hormone…More
With share prices tumbling and a massive drug-price fixing lawsuit hanging over its head, Mylan’s future is looking increasingly spooky.…More
